Table 2.
Published clinical trials of immunotherapies modulating adaptive immunity of ovarian cancer patients.
| Intervention | NCT/Author | Phase | Enrollment | Primary Endpoint | PFS | OS | ORR |
|---|---|---|---|---|---|---|---|
| CAR-T | |||||||
| Anti-Folate Receptor | Kershaw et al. | 1 | 14 recurrent FR+ OC | Safety and Activity | – | – | * |
| Anti-Mesothelin | Beatty et al. | 1 | 5 OC | Safety and Activity | – | – | 0/5 |
| Anti-CTLA4 | |||||||
| Ipilimumab | Hodi et al. | 1 | 9 Stage 4 OC | Safety and Activity | – | – | 0/9 |
| NCT01611558 | 2 | 40 RPS OC | DrAEs | – | – | 4/39 (10.3%) | |
| Nivolumab+Ipilimumab | Zamarin et al. NCT02498600 |
2 | 100 recurrent OC | ORR | 3.9 months | 28.1 months | 16/51 (31.4%) |
| Anti-PD-1 | |||||||
| Nivolumab | Hamanishi et al. | 2 | 20 RPR OC | Safety and Activity | 3.5 months | 20.0 months | 3/20 (15%) |
| Nivolumab + Bevacizumab | Liu et al. | 2 | 38 recurrent OC | ORR | 12.1 months in RPS 7.7 months in RPR |
– | 8/20 (40%) in RPS 3/18 (16.7%) in RPR |
| Pembrolizumab | Varga et al. | 1b | 26 PD-L1+ OC | ORR | 1.9 months | 13.8 months | 3/26 (11.5%) |
| Pembrolizumab | Matulonis et al. | 2 | Cohort A: 285 recurrent OC Cohort B: 91 recurrent OC |
ORR | Cohort A: 2.1 months Cohort B: 2.1 months |
Cohort A: - Cohort B: 17.6 months |
Cohort A: 7.4% Cohort B: 9.9% |
| Pembrolizumab + Niraparib | Konstantinopoulos et al. | 1/2 | Phase 1: 9 RPR OC Phase 2: 53 RPR OC |
Phase 1: Safety and RP2D Phase 2: ORR |
3.4 months | – | Integrated: 18% |
| Durvalumab + Olaparib + Cediranib | Zimmer et al. | 1 | 7 recurrent OC 1 peritoneal cancer 1 endomterial 1 TNBC |
RP2D | – | – | 4/9 (44%) |
| Durvalumab + Olaparib | Lampert et al. | 2 | 35 recurrent OC | ORR | 3.9 months | – | 5/35 (14%) |
| Durvalumab + Olaparib | Drew et al. | 2 | 32 BRCAmut, RPS OC | ORR | – | – | 20/32 (63%) |
| Anti-PD-L1 | |||||||
| Avelumab | Disis et al. NCT01772004 |
1b | 125 recurrent OC | ORR | 2.6 months | 11.2 months | 12/125 (9.6%) |
-Not reported; *No patients responded to treatment; RPR, recurrent platinum-sensitive; RPR, recurrent platinum-resistant; RP2D, Recommended phase 2 dose; TNBC, Triple-negative breast cancer; ORR, Overall response rate.